BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

...test to detect early-stage cancer and minimal residual disease based on DNA methylation sequencing. Sarepta, Hansa...
...Therapeutics Inc. (NASDAQ:SRPT) has gained an exclusive, global license to develop and promote imlifidase from Hansa...
...from Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) to treat mild to moderate COVID-19. BioCentury Staff IdeS, imlifidase Avigan, favipiravir (T-705) Hansa...
BioCentury | Jun 26, 2020
Regulation

Data Bytes: CHMP’s June opinions

...VX-445/VX-661/VX-770) Turalio, pexidartinib (PLX3397) Xiidra, lifitegrast (SAR 1118, SHP606) Zemdri, plazomicin (achn-490) Gilead Sciences Inc. Bristol Myers Squibb Co. Acceleron Pharma Inc. Hansa...
BioCentury | Jun 2, 2020
Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

...problems plaguing gene therapy -- immune responses against viral vectors -- by adapting a strategy Hansa...
...published a possible way around the problem. The approach centers on a bacterial enzyme that Hansa...
...idea is to deliver it just before a gene therapy to prevent anti-vector antibody responses. Hansa...
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

...first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa...
...He was global head of healthcare at Degroof Petercam Investment Bank. Robin Sawka, BioCentury Staff Acadia Pharmaceuticals Inc. Hansa...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...a veteran of Sorin Capital Management, Capmark Investments, Morgan Stanley and UBS Securities. Autoimmune company Hansa...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Epidiolex cannabidiol Seizures associated with tuberous sclerosis complex Phase III data; submit sNDA 1H19; 2H19 Hansa...
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

...she founded. Biophytis hired Samuel Agus to succeed her as CMO. He was VP of Hansa...
BioCentury | Mar 19, 2018
Company News

Management tracks: J&J, Alder, CVS

...effective April 2. He is VP of U.S. Immunology at AbbVie Inc. (NYSE:ABBV). Autoimmune company Hansa...
BioCentury | Mar 2, 2018
Clinical News

Hansa reports Phase II data of IdeS in kidney transplant patients

...donor-specific antibodies and safety. The product is a Streptococcus pyogenes enzyme that cleaves IgG antibodies. Hansa...
...donor-specific antibodies and safety Status: Interim Phase II data Milestone: Final Phase II data (3Q18) Chris Lieu IdeS Hansa...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...at Pfizer's R&D and Medical affairs division from 2002 to 2006. Autoimmune and transplant company Hansa...
Items per page:
1 - 10 of 30
BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

...test to detect early-stage cancer and minimal residual disease based on DNA methylation sequencing. Sarepta, Hansa...
...Therapeutics Inc. (NASDAQ:SRPT) has gained an exclusive, global license to develop and promote imlifidase from Hansa...
...from Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) to treat mild to moderate COVID-19. BioCentury Staff IdeS, imlifidase Avigan, favipiravir (T-705) Hansa...
BioCentury | Jun 26, 2020
Regulation

Data Bytes: CHMP’s June opinions

...VX-445/VX-661/VX-770) Turalio, pexidartinib (PLX3397) Xiidra, lifitegrast (SAR 1118, SHP606) Zemdri, plazomicin (achn-490) Gilead Sciences Inc. Bristol Myers Squibb Co. Acceleron Pharma Inc. Hansa...
BioCentury | Jun 2, 2020
Tools & Techniques

Spark’s approach to the problem of redosing AAV gene therapies

...problems plaguing gene therapy -- immune responses against viral vectors -- by adapting a strategy Hansa...
...published a possible way around the problem. The approach centers on a bacterial enzyme that Hansa...
...idea is to deliver it just before a gene therapy to prevent anti-vector antibody responses. Hansa...
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

...first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa...
...He was global head of healthcare at Degroof Petercam Investment Bank. Robin Sawka, BioCentury Staff Acadia Pharmaceuticals Inc. Hansa...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...a veteran of Sorin Capital Management, Capmark Investments, Morgan Stanley and UBS Securities. Autoimmune company Hansa...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Epidiolex cannabidiol Seizures associated with tuberous sclerosis complex Phase III data; submit sNDA 1H19; 2H19 Hansa...
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

...she founded. Biophytis hired Samuel Agus to succeed her as CMO. He was VP of Hansa...
BioCentury | Mar 19, 2018
Company News

Management tracks: J&J, Alder, CVS

...effective April 2. He is VP of U.S. Immunology at AbbVie Inc. (NYSE:ABBV). Autoimmune company Hansa...
BioCentury | Mar 2, 2018
Clinical News

Hansa reports Phase II data of IdeS in kidney transplant patients

...donor-specific antibodies and safety. The product is a Streptococcus pyogenes enzyme that cleaves IgG antibodies. Hansa...
...donor-specific antibodies and safety Status: Interim Phase II data Milestone: Final Phase II data (3Q18) Chris Lieu IdeS Hansa...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...at Pfizer's R&D and Medical affairs division from 2002 to 2006. Autoimmune and transplant company Hansa...
Items per page:
1 - 10 of 30